FDA-AstraZeneca Hearing
Similar Posts
Children’s Mental Health in the 108th Congress: The Good, The Bad, and The Ugly
Children’s Mental Health in the 108th Congress: The Good, The Bad, and The Ugly Wed, 15 Dec 2004 AHRP board member, Dr. Karen Effrem, provides a succinct overview of actions – the good, the bad, and the ugly–taken by the 108th Congress will have an impact on children’s health and…
Carefully Weigh Drug Firms’ Claims
The truth about the pharmaceutical industry and its corrupting influence on high ranking lawmakers and the near-total subversion of the FDA is spreading to the American hinterland. Below is an informed, intelligent editorial in the Shreveport Times, Louisiana that explains to readers why this industry is not to be trusted.
Johnson & Johnson stung by its own Advisory Committee–Natrecor should be strictly limited
Johnson & Johnson stung by its own Advisory Committee–Natrecor should be strictly limited Fri, 12 Aug 2005 Kudos go to Dr. Eugene Braunwald and the 10 members of the advisory committee that he heads. Contrary to Johnson & Johnson expectations, the committee recommended extensive warnings to physicians against prescribing Natrecor…
Disingenous Remarks from AMA President on Tort Reform – letter BMJ / NYT Test a Lawyer’s Ingenuity
Disingenous Remarks from AMA President on Tort Reform – letter BMJ / NYT Test a Lawyer’s Ingenuity Sun, 6 Mar 2005 Responding to an article in the BMJ about President Bush’s bill to restrict class action suits for medical malpractice-http://bmj.bmjjournals.com/cgi/content/full/330/7490/499-c – the president of the American Medical Association, Dr. John…
Reunion of Heavy Metal Music Band To Raise Awareness Against Forced Drugs
Anthrax Global Press Conference Friday, April 1, at 2:00 PM: Reunion of Heavy Metal Music Band To Raise Awareness Against Forced Drugs Wed, 30 Mar 2005 An unusual global press conference will kick off a week-end of heavy metal music and a public awareness campign. The press conference is scheduled…
Response to Washington Post Editorial “Missing Drug Data”
Today’s (6/30/04) editorial, “Missing Drug Data,” misses the point and argues with the pharmaceutical industry and its allies in the Congress, the NIH and the FDA that data can be selectively reported to satisfy commercial interests. This is a blatant attack on Karl Popper’s falsifiability principle on which empirical science depends to make progress. One needs all the data in order to verify the results of clinical or any other kind of research. Most academics and pundits know that any case can be made if allowed to manipulate the data and assumptions. The AMA, the medical journal editors, and Eliot Spitzer, all deserve applause from the Washington Post editor-not quibbling about the possible damage that somehow, somewhere might result from strict embrace of the principles and practice of scientific inquiry. It’s all about transparency.
John H. Noble, Jr.